Tryp Therapeutics Inc (TSE:TRYP) has released an update.
Tryp Therapeutics Inc. has announced the approval of their arrangement with Exopharm Limited, with all conditions met and anticipated finalization by May 1, 2024. The company’s shares are set to trade on the ASX under the new name Tryptamine Therapeutics Limited around May 15, 2024, following a voluntary trading halt of Tryp shares on the CSE and OTCQB starting April 29, 2024. Shareholders are advised to complete necessary documentation to receive their entitlements as Tryp shares will be delisted from the CSE and stop trading on the OTCQB post-arrangement.
For further insights into TSE:TRYP stock, check out TipRanks’ Stock Analysis page.
